BRIEF: Sichuan Biokin launches Hong Kong IPO, eyes Stock Connect program entry
Biopharmaceutical company Sichuan Biokin Pharmaceutical (2615.HK; 688506.SH) launched its Hong Kong IPO on Friday, aiming to raise up to HK$3.36 billion ($432 million) by selling 8.63 million shares for between…
2615.HK
688506.SHG
Recent Articles
RELATED ARTICLES
-
Sichuan Teway spices up Hong Kong’s hot IPO market
603317.SHG
-
Unisound launches modest IPO into crowded Hong Kong market
9678.HK
-
Helmed by new chairman, Best Mart 360 navigates changing Hong Kong landscape
2360.HK
- Intsig scans global financial markets for cash with Hong Kong IPO
-
BRIEF: Zenergy included in program making its stock available to Mainland China investors
3677.HK
-
Fibocom limps out of IPO gate, weighed down by sagging margins
0638.HK 300638.SHE
-
JD.com sets up Hong Kong bridgehead as real-time retail battle moves overseas
9618.HK JD.US
Discover hidden China stock gems in our weekly newsletter